Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CAPRICOR THERAPEUTICS, INC.CAPR · Entity 5337 | Director | January 05, 2026 | January 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CAPRICOR THERAPEUTICS, INC.
Report date January 05, 2026 · Filed January 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.81 · Expires 2036-01-05 | Direct | 15,500 |
Reported balance
After 2026-01-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-05 · Grant · Acquired 15,500 · Balance 15,500 F1: The shares vest 1/12th of the first day of each month, commencing February 1, 2026, with the last month vesting on December 31, 2026, until the stock option becomes fully vested and exercisable. The award pertains to annual board service. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Issuer if the reporting person's service to the Issuer terminates prior to vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest 1/12th of the first day of each month, commencing February 1, 2026, with the last month vesting on December 31, 2026, until the stock option becomes fully vested and exercisable. The award pertains to annual board service. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Issuer if the reporting person's service to the Issuer terminates prior to vesting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 17, 2019 Filed Dec 20, 2019 00:34 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantCommon Stock | 20,391 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-074514 · tm1926719d2_4.xml · nonDerivative · entry 1 Musket David B · CIK 0001310611 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,891 F1 · price: The Reporting Person on December 17, 2019, purchased 20,391 shares of the common stock of Capricor Therapeutics, Inc. (the "Issuer"), and accompanying amount of warrants to purchase up to an aggregate of 20,391 shares of the Issuer's common stock, at a combined purchase price of $1.226 per share of common stock and accompanying warrant, for a total cost of approximately US$25,000. Read SEC document |
| August 08, 2019 Filed Aug 10, 2019 01:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (right to buy) · Derivative | 8,750 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0001144204-19-039000 · tv527331_form4.xml · derivative · entry 1 Musket David B · CIK 0001310611 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,750 Underlying: Common Stock · 8,750 shares Expires 2029-08-08 F1 · derivative.exercise_date: 3,000 of the shares shall vest immediately. The remaining 5,750 shares will vest 1/48th on the first day of each month, commencing September 1, 2019, until the stock option becomes fully vested and exercisable. However, the option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:01 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (right to buy) · Derivative | 38,000 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001144204-18-000857 · tv482715_4.xml · derivative · entry 1 Musket David B · CIK 0001310611 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2028-01-02 F1 · derivative.exercise_date: 10,500 of the shares will vest 1/48th on the first day of each month, commencing February 1, 2018, until the stock option becomes fully vested and exercisable. The remaining 27,500 shares will vest 1/12 on the first day of each month, commencing February 1, 2018, with the last month vesting on December 31, 2018. However, the option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
| May 09, 2017 Filed May 11, 2017 18:32 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | PurchaseCommon Stock | 25,000 | $3.10 | $77,500.00 |
DisclosureSEC source: 0001144204-17-026397 · v466674_4.xml · nonDerivative · entry 1 Musket David B · CIK 0001310611 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · kind: The Reporting Person entered into a Subscription Agreement with Capricor Therapeutics, Inc. (the "Issuer") pursuant to which the Reporting Person, on May 5, 2017 purchased an aggregate of 25,000 shares of the Issuer's common stock at a purchase price of $3.10 per share for total cash proceeds of approximately US$77,500. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 02:42 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (right to buy) · Derivative | 36,060 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001144204-17-000701 · v456176_4.xml · derivative · entry 1 Musket David B · CIK 0001310611 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,060 Underlying: Common Stock · 36,060 shares Expires 2027-01-03 F1 · derivative.exercise_date: 8,560 of the shares will vest 1/48th on the first day of each month, commencing February 1, 2017, until the stock option becomes fully vested and exercisable. The remaining 27,500 shares will vest 1/12 on the first day of each month, commencing February 1, 2017, with the last month vesting on December 31, 2017. However, the option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.